CJC-1295 + Ipamorelin
Paired growth-hormone secretagogues — the "CJC/Ipa" protocol, distinct from the healing-blend family.
Evidence tier C · Not approved in Canada · Community risk: high — endocrine manipulation, self-dosed, and WADA-banned.
C
What it is
A paired growth-hormone-secretagogue protocol: CJC-1295 (a growth-hormone-releasing-hormone analog) plus Ipamorelin (a ghrelin-receptor / GH secretagogue). The logic is complementary stimulation of the body's own growth-hormone release. Often written "CJC/Ipa." Unlike Wolverine/GLOW/KLOW, this isn't a healing blend — it's hormone-axis manipulation, and it's sold both grey-market and through some longevity/wellness clinics.
What People Use it For
• Muscle gain, fat loss, sleep quality, recovery, and "anti-aging."
• Marketed as a gentler alternative to exogenous growth hormone.
• Sold both by grey-market vendors and some clinics — the clinic route is more traceable but still off-label for these uses.
What The Evidence Shows
Both compounds have some human pharmacology data — they do raise GH and IGF-1 markers. But the community's outcome claims (meaningful muscle, fat-loss, or anti-aging benefit from the pair, used chronically) are not established by robust trials.
Raising GH/IGF-1 is a biomarker change, not a demonstrated clinical benefit. And chronic manipulation of this axis carries its own risk questions that a short-term marker bump doesn't answer.
Regulatory Status - Canada
Not Health-Canada-approved for these uses. Both are WADA-prohibited — directly relevant for any competitive athlete. CJC-1295 has also been associated with an immunogenicity concern in some formulations.
Risks & Red Flags
• Unknown long-term safety for all three by injection; no controlled AE data for the combination.• Endocrine manipulation: chronically pushing the GH/IGF-1 axis has theoretical links to insulin resistance, fluid retention, joint issues, and — via IGF-1 — concerns relevant to cancer risk.
• Injection-site reactions; self-injection sterility.
• Unknown actual dose/purity from grey-market vials; reconstitution-math error.
• CJC-1295 immunogenicity in some preparations.
The Honest Bottom Line
This one is different from the healing blends, and the difference matters: you're not nudging a local tissue, you're manipulating a whole-body hormone axis. That axis has downstream effects — on blood sugar, on fluid, on IGF-1 — that don't fully switch off when you stop the injections. "Gentler than growth hormone" is marketing, not a safety guarantee. For an athlete it's also a doping-control problem. Raising a lab marker is easy; knowing that it's helping you rather than quietly setting up a problem is the part no grey-market vial can tell you.
How To Lower Your Risk
• Understand this is endocrine manipulation, not a supplement — the GH/IGF-1 axis has downstream effects that don't fully reverse when you stop.
• Athletes: this is a doping-control issue as well as a health one (both are WADA-prohibited).
• Anyone with cancer risk or history should weigh the IGF-1 concern with a clinician before considering it.
• Third-party testing minimum; sterile technique; never share vials.
• Tell a clinician — clinic-sourced doesn't mean risk-free, but it's more traceable than a grey-market vial.
Sources
• Component pharmacology: CJC-1295 and Ipamorelin raise GH/IGF-1 markers in human studies; outcome-level physique/anti-aging benefit not established by robust trials.
• WADA-prohibited; CJC-1295 immunogenicity noted in some formulations.
Substrate is an independent educational harm-reduction resource. It is not medical, legal, or regulatory advice, and it is not a substitute for a licensed clinician. Compounds discussed are largely unapproved in Canada; nothing here endorses their use. Confirm anything health-related with a qualified professional. Built by a medical-sciences student — not a seller and not a clinic.